Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
AVL9 cell migration associated (AVL9)
- Target
- AVL9
- Molecular classification
- Other (conserved regulator of intracellular trafficking and late secretory pathway), Single-pass membrane protein
01
Overview
AVL9 cell migration associated (commonly known as AVL9) is a conserved, multifunctional protein involved in regulating intracellular trafficking, cell polarity, and exocytic transport—all processes essential for cell migration and tissue organization[2][3][4][6]. Located on recycling endosomes and functioning as a single-pass membrane protein, AVL9 is evolutionarily conserved from yeast to humans. In cancer biology, especially colorectal carcinoma, AVL9 upregulation promotes cell migration through the regulation of EGFR expression, making it a potential therapeutic target and biomarker for tumor aggressiveness and metastasis[1][2]. Beyond cancer, AVL9 is genetically linked to other processes such as myopia. Studies in model organisms highlight its critical roles in polarized secretion, Golgi function, and actin cytoskeleton organization, implying broader effects on cell and tissue biology[2][3]. Currently, no approved drugs target AVL9 directly, but its pathway can be manipulated by EGFR inhibitors in cancer treatment[1].
- Other names
- KIAA0241Late secretory pathway protein AVL9 homologAVL9 homolog (S. cerevisiae)AVL9 cell migration associated
02
Mechanism of action
Not directly established; drugs like cetuximab act downstream by inhibiting EGFR, which AVL9 regulates in cancer cell migration
03
Biological functions
Cell migrationIntracellular traffickingCell polarityExocytic transportRegulation of EGFR expressionRegulation of cell–cell junctions
04
Disease associations
Cancer (especially colorectal carcinoma and lung adenocarcinoma)Potential role in myopia (genetic association)
05
Safety considerations
Not directly established; as AVL9 functions in cell migration and polarity, targeting it therapeutically could theoretically affect tissue organization and wound healing, but these effects are not reported in the literature
06
Interacting drugs
None directly established; EGFR inhibitors (e.g., cetuximab) can modulate AVL9’s pathway-mediated cell migration in cancers, but do not directly target AVL9
07
Biomarkers
High AVL9 expression is a potential biomarker for aggressive cancers, such as colorectal carcinoma and lung adenocarcinoma
Beyond the preview
Go deeper on AVL9 cell migration associated (AVL9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVL9 cell migration associated (AVL9).